Skip to main content
Premium Trial:

Request an Annual Quote

Blackstone Appoints Savage Chair; Millennium s Grigorenko Joins NuGen Board

NEW YORK, Aug. 28 - Expression Analysis, the Research Triangle Park, NC-based gene-analysis startup, said on Aug. 26 that it had hired Wendell Jones as senior research statistician.

 

Jones will provide customized statistical planning and analysis for company clients. He was previously senior software reliability engineer at IBM.

 

Expression Analysis, which has close ties to Duke, uses Affymetrix microarrays to provide gene testing and analysis services.

 


 

Michael Savage, former CEO of Molecular Simulations, has joined the board of Blackstone Computing as chair.

 

From 1991 to 1999, Savage was chief of MSI, now known as Accelrys. He currently runs a scientific consulting business in San Diego.

 

Blackstone, based in Worcester, Mass., provides life-sciences software.

 


 

NuGen said on Aug. 19 that Millennium Pharmaceuticals microarray expert Elena Grigorenko has joined the company's advisory board.

 

At Millennium, Grigorenko leads cross-site microarray platform-evaluation efforts to improve RNA-labeling efforts. Before joining that company in 2000, she directed the microarray core facility at the Wake Forest University School of Medicine.

 

NuGen, based in San Carlos, Calif., is developing linear-amplification technology for gene expression analysis.

 



Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more